Lyrica contains pregabalin, a medication primarily used in the management of neuropathic pain and certain neurological conditions. Pregabalin belongs to a class of medications commonly referred to as gabapentinoids and is structurally related to the neurotransmitter GABA, although it does not act directly on GABA receptors.
Pregabalin works by binding with high affinity to the alpha 2 delta (α2δ) subunit of voltage gated calcium channels within the central nervous system. This interaction reduces calcium dependent release of excitatory neurotransmitters involved in pain signaling and neuronal excitability, which contributes to pregabalin’s analgesic and anticonvulsant effects.
Pregabalin is particularly associated with the management of neuropathic pain, which develops when nerves themselves are damaged or functioning abnormally. Depending on the jurisdiction and clinical indication, pregabalin is used for conditions including diabetic peripheral neuropathic pain, postherpetic neuralgia, neuropathic pain associated with spinal cord injury, and fibromyalgia.
Pregabalin also has anticonvulsant activity and can be used as adjunctive therapy in patients with partial onset seizures. Its ability to reduce excessive neuronal signaling through calcium channel modulation contributes to this effect.
Unlike conventional opioid pain medications, pregabalin does not produce its therapeutic effects through opioid receptors. Its pharmacological activity is instead centered on modulation of neuronal calcium channels and neurotransmitter release.
This product provides:
- Active Ingredient: Pregabalin
- Brand: Lyrica
- Strength: 150mg per capsule
- Quantity: 100 Capsules
- Drug Class: Gabapentinoid / Anticonvulsant
- Dosage Form: Oral Capsule
- Common Uses: Neuropathic pain and adjunctive seizure treatment
Health Canada’s Drug Product Database currently lists Lyrica 150mg pregabalin capsules as a marketed prescription medication in Canada. Multiple generic 150mg pregabalin capsule formulations are also marketed or approved.
Pregabalin is eliminated primarily through the kidneys, and dose adjustment may be required in patients with reduced renal function. Renal function is therefore an important consideration when pregabalin therapy is prescribed.
Common adverse effects can include dizziness, drowsiness, blurred vision, difficulty concentrating, peripheral swelling, increased appetite, and weight gain. Because dizziness and sedation can impair coordination and reaction time, patients should understand how pregabalin affects them before driving or performing potentially hazardous activities.
Pregabalin should also be used cautiously with opioids, alcohol, sedatives, or other central nervous system depressants, as combining these substances can increase sedation and the risk of serious respiratory depression in susceptible patients.
Pregabalin should generally not be stopped abruptly after regular treatment. Current prescribing information recommends gradually tapering treatment over at least one week when discontinuing pregabalin to reduce the likelihood of withdrawal symptoms or increased seizure risk.
Lyrica is a prescription medication and should be used according to the directions of a qualified healthcare professional.
